翰宇药业: 2025年半年度业绩预告

Performance Forecast - The company expects a net profit of 142 million to 162 million yuan, a significant increase from a loss of 10.36 million yuan in the same period last year, representing a growth of 1470.82% to 1663.89% [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be between 122 million and 142 million yuan, compared to a loss of 59.72 million yuan last year, indicating a growth of 304.27% to 337.76% [1] Reasons for Performance Change - The increase in performance is attributed to several factors, including strong demand in international markets, approval and sales of liraglutide injection by the U.S. FDA, continuous growth in raw material exports, competitive market positioning of the company's products, and strict cost control measures [1]